Inventiva (NASDAQ:IVA) Hits New 1-Year Low – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) reached a new 52-week low during mid-day trading on Tuesday. The company traded as low as $3.10 and last traded at $3.12, with a volume of 3,264,826 shares changing hands. The stock had previously closed at $3.16.

Analyst Ratings Changes

IVA has been the topic of several recent research reports. Weiss Ratings lowered shares of Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. Guggenheim lifted their price objective on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Truist Financial lifted their price objective on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Cantor Fitzgerald initiated coverage on Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.86.

Inventiva Price Performance

The company has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.50.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $0.75 million for the quarter. As a group, sell-side analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Trading of Inventiva

A number of hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP purchased a new position in Inventiva in the first quarter valued at $1,111,000. Platt Investment Counsel LLC acquired a new position in shares of Inventiva in the third quarter worth about $45,000. Engineers Gate Manager LP raised its position in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after acquiring an additional 43,280 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Inventiva in the fourth quarter worth about $603,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.